Tela Bio Financials

TELA Stock  USD 3.14  0.11  3.63%   
Based on the analysis of Tela Bio's profitability, liquidity, and operating efficiency, Tela Bio is not in a good financial situation at this time. It has a very high probability of going through financial hardship in January. At present, Tela Bio's Total Stockholder Equity is projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 14.3 M, whereas Total Assets are forecasted to decline to about 63.7 M. Key indicators impacting Tela Bio's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio4.784.2274
Moderately Up
Slightly volatile
The essential information of the day-to-day investment outlook for Tela Bio includes many different criteria found on its balance sheet. An individual investor should monitor Tela Bio's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Tela Bio.

Net Income

(49 Million)

  
Understanding current and past Tela Bio Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Tela Bio's financial statements are interrelated, with each one affecting the others. For example, an increase in Tela Bio's assets may result in an increase in income on the income statement.
Please note, the presentation of Tela Bio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Tela Bio's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Tela Bio's management manipulating its earnings.

Tela Bio Stock Summary

Tela Bio competes with Profound Medical, Si Bone, Nevro Corp, Orthopediatrics Corp, and Orthofix Medical. TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patients anatomy. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania. Tela Bio operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 123 people.
Specialization
Health Care, Health Care Equipment & Services
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS8723811084
CUSIP872381108
LocationPennsylvania; U.S.A
Business Address1 Great Valley
SectorHealth Care Equipment & Supplies
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.telabio.com
Phone484 320 2930
CurrencyUSD - US Dollar

Tela Bio Key Financial Ratios

Tela Bio Key Balance Sheet Accounts

201920202021202220232024 (projected)
Total Assets67.9M86.5M62.5M67.9M78.0M63.7M
Other Current Liab3.5M6.0M8.2M10.5M14.7M8.0M
Net Tangible Assets28.1M46.4M17.8M11.8M13.6M14.3M
Net Debt(15.1M)(43.6M)(12.4M)(2.1M)(5.6M)(5.9M)
Retained Earnings(167.9M)(196.7M)(229.9M)(274.2M)(320.9M)(336.9M)
Accounts Payable3.2M652K2.4M1.5M1.7M1.6M
Cash45.3M74.4M43.9M42.0M46.7M44.2M
Long Term Debt30.2M30.8M31.5M39.9M40.5M32.4M
Net Receivables2.8M2.7M4.2M6.6M9.7M10.2M
Long Term Debt Total31.4M30.2M31.5M39.9M45.9M30.4M
Inventory4.6M3.9M7.7M11.8M13.2M7.4M
Other Current Assets2.3M4.5M6.5M2.0M2.1M2.8M
Total Liab37.0M37.4M42.4M53.6M59.2M59.2M
Net Invested Capital61.2M79.9M51.6M54.2M59.4M62.4M
Total Current Assets64.3M83.2M59.1M62.4M71.7M59.5M
Net Working Capital57.6M76.6M48.5M50.0M54.8M48.6M
Common Stock11K14K15K19K24K15.2K
Capital Stock11K14K15K19K24K15.2K
Intangible Assets2.9M2.6M2.3M2.5M2.1M2.1M

Tela Bio Key Income Statement Accounts

201920202021202220232024 (projected)
Net Interest Income(3.6M)(3.6M)(3.6M)(4.1M)(5.1M)(5.3M)
Interest Expense3.6M3.6M3.6M4.1M5.2M4.1M
Total Revenue15.4M18.2M29.5M41.4M58.5M61.4M
Gross Profit9.3M11.2M18.8M27.0M40.1M42.1M
Operating Income(19.2M)(25.3M)(29.5M)(39.0M)(44.1M)(41.9M)
Ebit(19.2M)(25.2M)(29.7M)(40.2M)(41.4M)(43.5M)
Research Development4.2M4.3M6.7M8.9M9.6M6.9M
Ebitda(18.8M)(24.7M)(29.1M)(39.1M)(40.6M)(42.7M)
Cost Of Revenue6.2M7.0M10.7M14.4M18.3M10.0M
Income Before Tax(22.4M)(28.8M)(33.3M)(44.3M)(46.7M)(49.0M)
Net Income(25.8M)(31.9M)(36.1M)(44.3M)(46.7M)(49.0M)
Income Tax Expense3.4M3.1M2.8M41K640.1K608.1K

Tela Bio Key Cash Accounts

201920202021202220232024 (projected)
Change To Inventory(1.8M)(620K)(5.2M)(6.1M)(2.7M)(2.9M)
Investments(12.0M)9.1M(627K)(1.9M)(1.5M)(1.5M)
Change In Cash28.0M29.1M(30.5M)(1.9M)5.0M5.2M
Free Cash Flow(28.2M)(24.6M)(31.1M)(42.6M)(41.5M)(43.5M)
Depreciation582K525K535K1.2M808K645.3K
Other Non Cash Items2.1M1.8M2.1M4.1M1.6M2.1M
Capital Expenditures2.7M167K627K1.9M611K1.2M
Net Income(22.4M)(28.8M)(33.3M)(44.3M)(46.7M)(49.0M)
End Period Cash Flow45.3M74.4M43.9M42.0M47.0M44.2M
Change To Netincome2.6M4.0M5.8M6.9M8.0M5.1M

Tela Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Tela Bio's current stock value. Our valuation model uses many indicators to compare Tela Bio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Tela Bio competition to find correlations between indicators driving Tela Bio's intrinsic value. More Info.
Tela Bio is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Tela Bio's Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Tela Bio's earnings, one of the primary drivers of an investment's value.

Tela Bio Systematic Risk

Tela Bio's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Tela Bio volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Tela Bio correlated with the market. If Beta is less than 0 Tela Bio generally moves in the opposite direction as compared to the market. If Tela Bio Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Tela Bio is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Tela Bio is generally in the same direction as the market. If Beta > 1 Tela Bio moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Tela Bio Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Tela Bio's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Tela Bio growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.13

At present, Tela Bio's Price Earnings To Growth Ratio is projected to drop slightly based on the last few years of reporting.

Tela Bio December 1, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Tela Bio help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Tela Bio. We use our internally-developed statistical techniques to arrive at the intrinsic value of Tela Bio based on widely used predictive technical indicators. In general, we focus on analyzing Tela Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Tela Bio's daily price indicators and compare them against related drivers.

Complementary Tools for Tela Stock analysis

When running Tela Bio's price analysis, check to measure Tela Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tela Bio is operating at the current time. Most of Tela Bio's value examination focuses on studying past and present price action to predict the probability of Tela Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tela Bio's price. Additionally, you may evaluate how the addition of Tela Bio to your portfolios can decrease your overall portfolio volatility.
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Equity Valuation
Check real value of public entities based on technical and fundamental data
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Global Correlations
Find global opportunities by holding instruments from different markets